Estrogen-containing contraceptive use linked to lower odds of CRS without nasal polyps<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Feb. 13, 2026 (HealthDay News) — Menopause is not associated with chronic rhinosinusitis (CRS), while estrogen-containing contraceptive use is associated with reduced odds of CRS without nasal polyps (CRSsNP), according to a study published in the February issue of Otolaryngology-Head and Neck Surgery<\/em>.<\/p>\n Abraham Ahn, from the University of Illinois Chicago, and colleagues conducted a cross-sectional analysis using a national dataset of adults from the All of Us<\/em> Research Program to examine the association of menopause and systemic hormonal contraceptive (SHC) use with both CRS with nasal polyps (CRSwNP) and CRSsNP. The study used data from 239,564 participants.<\/p>\n The researchers observed no significant difference in the odds of CRS for postmenopausal participants versus premenopausal patients (odds ratio, 1.02; 95 percent confidence interval, 0.94 to 1.11). Progestin-only contraceptives were not associated with CRS compared with no SHC use, while the odds of CRSsNP were lower in association with estrogen-containing contraceptive use (odds ratio, 0.71; 95 percent confidence interval, 0.64 to 0.80), but the odds of CRSwNP were not lower (odds ratio, 0.82; 95 percent confidence interval, 0.51 to 1.25). Among participants without CRS and among those with CRSsNP, estrogen-containing contraceptive use was associated with decreased serum neutrophil concentration (\u03b2 = \u22121.29 and \u22121.66, respectively) compared with no SHC use.<\/p>\n “Ultimately, this work has the potential to improve risk stratification and inform hormone-related therapy recommendations for women with CRS,” senior author Victoria S. Lee, M.D., also from the University of Illinois Chicago, said in a statement.<\/p>\n